These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15884403)

  • 21. Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention.
    Vergara-Jimenez J; Tricoci P
    Vasc Health Risk Manag; 2010 Mar; 6():39-45. PubMed ID: 20234778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction.
    Dangas GD; Caixeta A; Mehran R; Parise H; Lansky AJ; Cristea E; Brodie BR; Witzenbichler B; Guagliumi G; Peruga JZ; Dudek D; Möeckel M; Stone GW;
    Circulation; 2011 Apr; 123(16):1745-56. PubMed ID: 21482968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
    Bertrand OF; Rodés-Cabau J; Rinfret S; Larose E; Bagur R; Proulx G; Gleeton O; Costerousse O; De Larochellière R; Roy L
    Am J Cardiol; 2009 Nov; 104(9):1235-40. PubMed ID: 19840568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
    Di Sciascio G; Mangiacapra F
    J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
    [No Abstract]   [Full Text] [Related]  

  • 27. New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines.
    Spinler SA; Hilleman DE; Cheng JW; Howard PA; Mauro VF; Lopez LM; Munger MA; Gardner SF; Nappi JM
    Ann Pharmacother; 2001 May; 35(5):589-617. PubMed ID: 11346067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The benefits of platelet glycoprotein IIb/IIIa receptor inhibition during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: drug-specific or class effect?
    Brener SJ
    J Am Coll Cardiol; 2009 May; 53(18):1674-6. PubMed ID: 19406343
    [No Abstract]   [Full Text] [Related]  

  • 30. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study.
    Armstrong PW;
    Eur Heart J; 2006 Jul; 27(13):1530-8. PubMed ID: 16757491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN; Wong SC; Bergman G; Minutello RM
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much?
    Duffy B; Bhatt DL
    Am J Cardiovasc Drugs; 2005; 5(5):307-18. PubMed ID: 16156686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions].
    Niessner A; Niessner H; Huber K
    Herz; 2001 Apr; 26 Suppl 1():36-41. PubMed ID: 11349625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What have We learned from ESPRIT? What will we learn from TARGET?
    Ferguson JJ
    J Invasive Cardiol; 2000 Jun; 12(6):317-9. PubMed ID: 10859719
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic therapy in patients undergoing coronary angioplasty.
    Popma JJ; Weitz J; Bittl JA; Ohman EM; Kuntz RE; Lansky AJ; King SB
    Chest; 1998 Nov; 114(5 Suppl):728S-741S. PubMed ID: 9822074
    [No Abstract]   [Full Text] [Related]  

  • 37. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic prevention of acute ischemic complications of coronary angioplasty.
    Wheeldon N; Cumberland D
    Cathet Cardiovasc Diagn; 1997 Nov; 42(3):249-56. PubMed ID: 9367094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antithrombotic treatment protocols in interventional cardiology].
    Barragan P; Teuma X; Botosezzy I; Bouvier JL; Comet B; Commeau P; Macaluso G; Roquebert PO
    Arch Mal Coeur Vaiss; 2001 Nov; 94(11 Suppl):1267-73. PubMed ID: 11794968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.